We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Anika Therapeutics Inc | NASDAQ:ANIK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.08 | -0.31% | 25.89 | 24.00 | 28.60 | 26.105 | 25.64 | 25.94 | 49,041 | 22:30:00 |
“We’re excited to attend the 2018 AAOS Annual Meeting to showcase our expansive orthopedic product portfolio, and proprietary HA-based technologies which fuel our thriving R&D pipeline,” said Joseph Darling, President and newly named CEO of Anika Therapeutics. “AAOS coincides with a transformational time for Anika as we build our direct commercialization operations to support the launch of our innovative combination viscosupplement, CINGAL®, and accelerate our clinical development and R&D efforts to yield a series of commercial, regulatory and clinical milestones over the next 12 to 18 months. We look forward to introducing Anika and its portfolio to the 30,000-plus members of the global orthopedic surgery community at AAOS, and forging relationships with key stakeholders who will be critical to the success of our direct sales and marketing efforts.”
Below are highlights of Anika’s planned activities at the 2018 AAOS Annual Meeting:
“Our participation in the 2018 AAOS Annual Meeting represents an important opportunity for Anika to engage U.S. orthopedic medicine thought-leaders about CINGAL, and showcase both real-world evidence from its successful launches overseas and clinical evidence from the first CINGAL Phase III study, to validate its benefits and advantages over currently available single-agent viscosupplements,” said Joseph Darling.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung, 781-457-9000 Chief Financial Officer | For Media Inquiries: Pure Communications Sonal Vasudev, 917-523-1418, sonal@purecommunicationsinc.com |
1 Year Anika Therapeutics Chart |
1 Month Anika Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions